Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Exclusion Criteria

• •Age \< 18 years or legal age of adulthood, whichever is greater
• •LDL-C \< 70 mg/dL (1.81 mmol/L) and with cardiovascular disease
• •LDL-C \< 100 mg/dL (2.59 mmol/L) and without cardiovascular disease
• •Fasting serum triglycerides \> 400 mg/dL (4.52 mmol/L)
• •Known history of homozygous familial hypercholesterolemia
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.